X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse IPCA Labs with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ACTAVIS (US) - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   ACTAVIS
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ACTAVIS
Dec-14
IPCA LABS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs69518,853-   
Low Rs40011,500-   
Sales per share (Unadj.) Rs260.23,394.9-  
Earnings per share (Unadj.) Rs19.0-423.7-  
Cash flow per share (Unadj.) Rs33.1311.5-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.07,363.5-  
Shares outstanding (eoy) m126.20265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.5 47.1%   
Avg P/E ratio x28.9-35.8 -80.6%  
P/CF ratio (eoy) x16.648.7 34.0%  
Price / Book Value ratio x2.62.1 124.7%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1204,035,446 1.7%   
No. of employees `00013.321.6 61.4%   
Total wages/salary Rs m7,3590-   
Avg. sales/employee Rs Th2,477.441,792.4 5.9%   
Avg. wages/employee Rs Th555.20-   
Avg. net profit/employee Rs Th180.6-5,215.2 -3.5%   
INCOME DATA
Net Sales Rs m32,836902,715 3.6%  
Other income Rs m418-2,253 -18.6%   
Total revenues Rs m33,254900,462 3.7%   
Gross profit Rs m4,505115,967 3.9%  
Depreciation Rs m1,777195,471 0.9%   
Interest Rs m24028,473 0.8%   
Profit before tax Rs m2,905-110,230 -2.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,086 0.0%   
Tax Rs m511-5,667 -9.0%   
Profit after tax Rs m2,394-112,649 -2.1%  
Gross profit margin %13.712.8 106.8%  
Effective tax rate %17.65.1 342.2%   
Net profit margin %7.3-12.5 -58.4%  
BALANCE SHEET DATA
Current assets Rs m19,455475,615 4.1%   
Current liabilities Rs m10,076346,863 2.9%   
Net working cap to sales %28.614.3 200.3%  
Current ratio x1.91.4 140.8%  
Inventory Days Days9858 168.7%  
Debtors Days Days6766 101.0%  
Net fixed assets Rs m20,260110,230 18.4%   
Share capital Rs m2520-   
"Free" reserves Rs m26,6330-   
Net worth Rs m26,8861,957,955 1.4%   
Long term debt Rs m2,3401,026,007 0.2%   
Total assets Rs m41,1733,588,288 1.1%  
Interest coverage x13.1-2.9 -456.1%   
Debt to equity ratio x0.10.5 16.6%  
Sales to assets ratio x0.80.3 317.0%   
Return on assets %6.4-2.3 -272.8%  
Return on equity %8.9-5.8 -154.8%  
Return on capital %10.8-3.0 -357.5%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Net fx Rs m10,7590-   
CASH FLOW
From Operations Rs m3,411155,014 2.2%  
From Investments Rs m-1,354-371,162 0.4%  
From Financial Activity Rs m-1,304208,539 -0.6%  
Net Cashflow Rs m753-7,609 -9.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.11 Rs / USD

Compare IPCA LABS With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare IPCA LABS With: UNICHEM LAB  PLETHICO PHARMA  LUPIN  SUN PHARMA  AJANTA PHARMA  



Today's Market

Indian Indices End Marginally Higher, Oil Prices, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed volatility during closing hours yesterday and ended their day marginally higher.

Related Views On News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

Sensex Nearing All-Time Highs: Stocks to Buy in this Rally(Profit Hunter)

Mar 14, 2019

The BSE Sensex is heating up. In just a few days, the benchmark index is up 3%. Is this rally sustainable? Richa finds out...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Mar 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS